An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Devendra Barlewar, a 47-year-old scientist, successfully received a rare third kidney transplant at Amrita Hospital, leaving ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

A new thesis from Karolinska Institutet aims to advance our understanding of the bidirectional relationship between ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Lack of steady income can cause patients to face difficulties in bearing treatment costs that can reach up to RM40,000 a year ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with incident bipolar disorder (BD), according to a study published online Feb. 11 ...